Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Oregon Health and Science University Centocor, Inc. |
---|---|
Information provided by: | Oregon Health and Science University |
ClinicalTrials.gov Identifier: | NCT00273390 |
This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha (TNF-alpha) and its receptors using Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA) is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy.
Condition | Intervention |
---|---|
Uveitis |
Drug: Remicade (infliximab) |
Study Type: | Interventional |
Official Title: | The Use of Remicade (Infliximab) in the Management of Vision-Threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression |
Ages Eligible for Study: | 9 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | James T Rosenbaum, MD | Oregon Health and Science University |
Study Director: | Eric B Suhler, MD | Oregon Health and Science University |
Study Director: | Justine Smith, MBBS, Phd | Oregon Health and Science University |
Study ID Numbers: | e1473 |
Study First Received: | January 5, 2006 |
Last Updated: | February 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00273390 |
Health Authority: | United States: Institutional Review Board |
Infliximab Uveitis Eye Diseases |
Anti-Inflammatory Agents Uveal Diseases Therapeutic Uses Gastrointestinal Agents |
Antirheumatic Agents Dermatologic Agents Pharmacologic Actions |